ZG111

ZG111 is a **small molecule drug** developed as a selective **agonist of caseinolytic mitochondrial matrix peptidase proteolytic subunit (ClpP)**. It promotes ClpP-mediated degradation of mitochondrial respiratory chain complexes, leading to mitochondrial dysfunction and the activation of the JNK/c-Jun pathway as well as endoplasmic reticulum stress responses, specifically suppressing pancreatic ductal adenocarcinoma cell proliferation in vitro[1][3][7]. This results in disrupted mitochondrial proteome homeostasis, cell cycle arrest, and apoptosis in certain cancer cell types. Its molecular formula is C30H33BrN4O3, and its development has focused on oncology indications including neoplasms and leukemia[1][7].

Brand names

ZG111ZG-111ZG 111

Other names

ZG111ZG-111ZG 111